Skip to main content
SpringerLink
Log in

Diagnostic criteria, classification, and prognosis of acute leukemias

  • Chapter
  • First Online:
Handbook of Acute Leukemia

  • 1540 Accesses

Abstract

The currently accepted classification of acute leukemias was published in 2008 as part of the 4th edition of the World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. Lyon, France: IARC; 2008.

    Google Scholar 

  2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391-2405.

    Google Scholar 

  3. Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). Blood. 2010;116:2742-2751.

    Google Scholar 

  4. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367-1376.

    Google Scholar 

  5. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117:2137-2145.

    Google Scholar 

  6. Mauritzson N, Albin M, Rylander L, et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002;16:2366-2378.

    Google Scholar 

  7. Walter RB, Othus M, Burnett AK, et al. Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood. 2013;121:2424-2431.

    Google Scholar 

  8. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.

    Google Scholar 

  9. Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118:3785-3793.

    Google Scholar 

  10. McGregor S, McNeer J, Gurbuxani S. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. Semin Diagn Pathol. 2012;29:2-11.

    Google Scholar 

  11. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012;22:153-166.

    Google Scholar 

  12. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.

    Google Scholar 

  13. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354-365.

    Google Scholar 

  14. Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515-4523.

    Google Scholar 

  15. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.

    Google Scholar 

  16. Dufour A, Schneider F, Metzeler K, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28:570-577.

    Google Scholar 

  17. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373:1136-1152.

    Google Scholar 

  18. Roug AS, Hansen MC, Nederby L, Hokland P. Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age. Br J Haematol. 2014;167:162-176.

    Google Scholar 

  19. Haferlach T. How does one work-up an acute myeloid leukemia patient in the molecular era? http://learningcenter.ehaweb.org/eha/2015/20th/103570/torsten.haferlach.how.does.one. work.up.an.aml.patient.in.the.molecular.era.html?f=m6t1576. Accessed August 12, 2016.

  20. Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014:8-13.

    Google Scholar 

  21. Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000-2008.

    Google Scholar 

  22. Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia:which platforms are ready for “prime time”? Blood. 2014;124:3345-3355.

    Google Scholar 

  23. Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422-433.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hematology and Oncology, University of Munich, Munich, Germany

    Klaus Metzeler

Authors
  1. Klaus Metzeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Internal Medicine III, Munich University Hospital, Munich, Germany

    Wolfgang Hiddemann

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Metzeler, K. (2016). Diagnostic criteria, classification, and prognosis of acute leukemias. In: Hiddemann, W. (eds) Handbook of Acute Leukemia. Adis, Cham. https://doi.org/10.1007/978-3-319-26772-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26772-2_4

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-26770-8

  • Online ISBN: 978-3-319-26772-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation